Sheng Chen

发表

Diagnostic performance of a novel high-resolution dedicated axillary PET system in the assessment of regional nodal spread of disease in early breast cancer.

Junjie Li, Guangyu Liu, R. Shui, 2021, Quantitative imaging in medicine and surgery.

Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women

Keda Yu, Z. Shao, S. Hao, 2015, PloS one.

Obesity or Overweight Is Associated with Worse Pathological Response to Neoadjuvant Chemotherapy among Chinese Women with Breast Cancer

Keda Yu, Z. Shao, Can-ming Chen, 2012, PloS one.

Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer

Dachang Ma, Xun Li, Keda Yu, 2022, Frontiers in Immunology.

Delayed initiation of radiation therapy is associated with inferior outcomes for breast cancer patients with hormone receptor-negative tumors after breast-conserving surgery.

Keda Yu, Guangyu Liu, Jiong Wu, 2021, Gland surgery.

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer

Z. Shao, Sheng Chen, Qi Liu, 2017, OncoTargets and therapy.

A Novel High-resolution Dedicated Axillary PET Improve Sensitivity in the Assessment of Regional Nodal Spread of Disease in Early Breast Cancer.

Junjie Li, Guangyu Liu, R. Shui, 2020 .

Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study

Keda Yu, G. Di, Z. Shao, 2015, Oncotarget.

Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial

E. Song, Bing-he Xu, Wentao Yang, 2015, Oncotarget.

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy

Jiong Wu, Z. Shao, Can-ming Chen, 2013, World Journal of Surgical Oncology.

Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial

Junjie Li, Guangyu Liu, Z. Shao, 2022, Cancer Biology & Medicine.

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival

Z. Shao, Y. Gong, P. Ji, 2022, Frontiers in Immunology.

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

Keda Yu, G. Di, Z. Shao, 2016, BMC Cancer.

A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients

G. Di, Z. Shao, Yizhou Jiang, 2016, Scientific Reports.

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin

Z. Shao, Sheng Chen, Ruo-Xi Wang, 2016, Scientific Reports.

The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer.

Z. Shao, R. Luo, Yizhou Jiang, 2016, International journal of oncology.

Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study

Z. Shao, Y. Gong, P. Ji, 2020, Breast Cancer Research and Treatment.

eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.

Xiao-En Xu, Z. Shao, Sheng Chen, 2019, Annals of translational medicine.

Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.

Z. Shao, Sheng Chen, Ying-Feng Zhou, 2018, The oncologist.

Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients

Z. Shao, Sheng Chen, Ruo-Xi Wang, 2018, BMC Cancer.

The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy

Keda Yu, Z. Shao, Yizhou Jiang, 2013, Clinical Cancer Research.

Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy

Z. Shao, Can-ming Chen, Sheng Chen, 2015, Oncotarget.

A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline‐containing neoadjuvant chemotherapy for breast cancer

Keda Yu, Z. Shao, Can-ming Chen, 2012, Journal of surgical oncology.

An Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Favorable Response and Prognosis in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy

Xin Hu, Jiong Wu, Z. Shao, 2014, PloS one.

CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer

X. Bian, X. Yao, Z. Shao, 2018, PLoS biology.

PD‐L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy

Z. Shao, Wen‐tao Yang, Sheng Chen, 2017, International journal of cancer.

Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy

Wentao Yang, Z. Shao, Sheng Chen, 2016, Oncotarget.

A Prognostic Model for Triple-Negative Breast Cancer Patients Based on Node Status, Cathepsin-D and Ki-67 Index

Z. Shao, Zhe-bin Liu, Liang Huang, 2013, PloS one.

Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis

Z. Shao, Can-ming Chen, Sheng Chen, 2016, Breast Cancer Research and Treatment.

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy

Junjie Li, Guangyu Liu, Jiong Wu, 2016, Oncotarget.

Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients

Z. Shao, Sheng Chen, Ruo-Xi Wang, 2018, BMC cancer.

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer

Guangyu Liu, Jiong Wu, Z. Shao, 2015, International journal of nanomedicine.

Effect of large tumor size on cancer-specific mortality in node-negative breast cancer.

Keda Yu, Jiong Wu, Z. Shao, 2012, Mayo Clinic proceedings.

E. Song, Bing-he Xu, Wentao Yang, 2015, Oncotarget.

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer

Guangyu Liu, Jiong Wu, Z. Shao, 2015, International journal of nanomedicine.